The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2025

Filed:

Jul. 20, 2023
Applicant:

Vakston, Inc., Beverly, MA (US);

Inventors:

Todd C. Zion, Marblehead, MA (US);

Thomas M. Lancaster, Wenham, MA (US);

Thillainayagam Sathiyaseelan, Lexington, MA (US);

Kexin Huang, San Mateo, CA (US);

Assignee:

Vakston, Inc., Beverly, MA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/215 (2006.01); A61P 31/14 (2006.01); C07K 14/165 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/215 (2013.01); A61P 31/14 (2018.01); C07K 14/165 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55588 (2013.01);
Abstract

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.


Find Patent Forward Citations

Zion, Todd. (2025). Antigen specific immunotherapy for covid-19 fusion proteins and methods of use (U.S. Patent No. 12343393). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12343393

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…